

510(k) Submissions Workshop

AdvaMed Office 1301 Pennsylvania Ave. N.W. Suite 400 Washington, D.C. February 3 – 4, 2025

<u>Feb 3, 2025</u>	
8:30 – 9:00 am	Registration Check-In and Continental Breakfast
9:00 – 9:05 am	Welcome and Introductions
9:05 – 10:30 am	 The Law and Regulations Sally Maher, Regulatory Consultant, Sally Maher Consulting 510(k) definition 510 and 513 FDCA Guidance for 510(k): general & product specific How to find it How to use it Different types of 510(k)s; which to use Review of bundling 510(k)s FDA Product Codes – Activity
10:30 – 10:45 am	Break
10:45 am – 12:00 pm	 510(k) Strategy and Planning Tony Blank, Senior Director of Regulatory Affairs, AtriCure Staff involved Role of each function RA responsibilities Use of guidance Global considerations Pre-submissions Predicates Breakthrough Devices Program Safer Technologies Program
12:00 – 1:00 pm	Networking Lunch
1:00 – 2:15 pm	 Preparing the Submission Jemin Jay Dedania, Senior Director of Regulatory Affairs and Compliance at the National Evaluation System for health Technology, MDIC Melissa Hall, Founder and Principal Consultant, Statera Regulatory Consulting General information including how to select a predicate device Assembling the 510(k) eSTAR

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



2:15 – 2:30 pm Break

2:30 - 3:15 pm **The FDA Review Process** Alexia Haralambous, Senior Principal, RQM+ How it works at FDA • FDA/industry interactions Refuse to Accept Submission Issue meetings FDA holds Interactive review Least Burdensome flag Current pilots **Networking Reception** 3:15 – 4:15 pm Feb 4, 2025 8:30 - 9:00 am **Continental Breakfast** 9:00 - 10:15 am **Clearance: Launch and After** Tony Blank, Senior Director of Regulatory Affairs, AtriCure What clearance does and does not mean Promotional practices for 510(k) devices • FDA FTC 0 Complaint Handling and MDRs . When to File a New 510(k) for Device Modifications Catch-up 510(k)s 10:15 - 10:30 am Break 10:30 - 11:00 am De Novo Elaine Tseng, Partner, King & Spalding Definition of a De Novo • Final Rule on De Novo When De Novo is used Differentiation from 510(k) • 11:00 – 11:30 am **Regulatory Strategy for De Novo** Ginny Hu, Director, Regulatory Affairs, Dexcom Key eligibility criteria • Benefit-risk analysis

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



Events & Education	
11:30 am – 12:00 pm	 Preparing the De Novo Submission Bryan Osborne, Senior Manager, Regulatory Affairs, Dexcom Content Assembling the submission
12:00 – 1:00 pm	Networking Lunch
1:00 – 1:30 pm	 FDA Review Process for De Novo Elaine Tseng, Partner, King & Spalding Use of Pre-Submission meeting Rationale for De Novo Clinical Protocols Special Controls Benefit-Risk Considerations
1:30 – 2:00 pm	 Maintenance of a Granted De Novo Laura Rose, PhD, Engagement Partner, Bruder Consulting & Venture Group Post-market requirements Classification Order De Novo database, granting order, decision summary Use as a predicate Making changes to granted De Novo device
2:00 – 2:15 pm	Break
2:15 – 4:15 pm	 Applied Learning and Breakout Discussions Tony Blank, Senior Director of Regulatory Affairs, AtriCure * In person participants, only 510(k) & De Novo Recap Facilitated Breakout Group Deep Dive - Hypothetical Case Studies & Key Takeaways Regroup for Q&A
4:15 pm	Adjournment

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.